Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18507
Country/Region: Kenya
Year: 2018
Main Partner: Centre for Health Solutions
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $3,225,453 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $169,424
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,137,030
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $305,010
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,462,399
Treatment: Pediatric Treatment (PDTX) $151,590
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 2
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 1
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 2
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 4
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 4
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 6
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 6
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 1
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 1
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 1
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 6
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 1
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 1
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 17
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 29
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 17
GEND_GBV Number of people receiving post-GBV care 2019 46
HTS_SELF 2019 650
HTS_SELF 15-19, Female, Directly-Assisted 2019 36
HTS_SELF 15-19, Female, Unassisted 2019 36
HTS_SELF 15-19, Male, Directly-Assisted 2019 12
HTS_SELF 15-19, Male, Unassisted 2019 12
HTS_SELF 20-24, Female, Directly-Assisted 2019 36
HTS_SELF 20-24, Female, Unassisted 2019 36
HTS_SELF 20-24, Male, Directly-Assisted 2019 12
HTS_SELF 20-24, Male, Unassisted 2019 12
HTS_SELF 25-29, Female, Directly-Assisted 2019 36
HTS_SELF 25-29, Female, Unassisted 2019 36
HTS_SELF 25-29, Male, Directly-Assisted 2019 12
HTS_SELF 25-29, Male, Unassisted 2019 12
HTS_SELF 30-34, Female, Directly-Assisted 2019 36
HTS_SELF 30-34, Female, Unassisted 2019 36
HTS_SELF 30-34, Male, Directly-Assisted 2019 12
HTS_SELF 30-34, Male, Unassisted 2019 12
HTS_SELF 35-39, Female, Directly-Assisted 2019 36
HTS_SELF 35-39, Female, Unassisted 2019 36
HTS_SELF 35-39, Male, Directly-Assisted 2019 12
HTS_SELF 35-39, Male, Unassisted 2019 12
HTS_SELF 40-49, Female, Directly-Assisted 2019 36
HTS_SELF 40-49, Female, Unassisted 2019 36
HTS_SELF 40-49, Male, Directly-Assisted 2019 12
HTS_SELF 40-49, Male, Unassisted 2019 12
HTS_SELF 50+, Female, Directly-Assisted 2019 36
HTS_SELF 50+, Female, Unassisted 2019 36
HTS_SELF 50+, Male, Directly-Assisted 2019 12
HTS_SELF 50+, Male, Unassisted 2019 12
HTS_SELF Directly-Assisted 2019 325
HTS_SELF FSW, Directly-Assisted 2019 434
HTS_SELF MSM, Directly-Assisted 2019 97
HTS_SELF PWID, Directly-Assisted 2019 39
HTS_SELF Unassisted 2019 325
HTS_SELF Unassisted - Other 2019 32
HTS_SELF Unassisted - Self 2019 161
HTS_SELF Unassisted - Sex Partner 2019 129
HTS_TST 15-19, Female, Negative 2019 317
HTS_TST 15-19, Male, Negative 2019 182
HTS_TST 20-24, Female, Negative 2019 1,083
HTS_TST 20-24, Male, Negative 2019 588
HTS_TST 25-29, Female, Negative 2019 52
HTS_TST 25-29, Female, Negative 2019 138
HTS_TST 25-29, Female, Negative 2019 602
HTS_TST 25-29, Female, Negative 2019 1,458
HTS_TST 25-29, Female, Negative 2019 23,614
HTS_TST 25-29, Female, Negative 2019 3,585
HTS_TST 25-29, Female, Negative 2019 458
HTS_TST 25-29, Male, Negative 2019 65
HTS_TST 25-29, Male, Negative 2019 5
HTS_TST 25-29, Male, Negative 2019 92
HTS_TST 25-29, Male, Negative 2019 204
HTS_TST 25-29, Male, Negative 2019 16,155
HTS_TST 25-29, Male, Negative 2019 73
HTS_TST 30-34, Female, Negative 2019 45
HTS_TST 30-34, Female, Negative 2019 160
HTS_TST 30-34, Female, Negative 2019 692
HTS_TST 30-34, Female, Negative 2019 1,664
HTS_TST 30-34, Female, Negative 2019 25,843
HTS_TST 30-34, Female, Negative 2019 3,660
HTS_TST 30-34, Female, Negative 2019 524
HTS_TST 30-34, Male, Negative 2019 68
HTS_TST 30-34, Male, Negative 2019 6
HTS_TST 30-34, Male, Negative 2019 111
HTS_TST 30-34, Male, Negative 2019 243
HTS_TST 30-34, Male, Negative 2019 19,961
HTS_TST 30-34, Male, Negative 2019 87
HTS_TST 35-39, Female, Negative 2019 57
HTS_TST 35-39, Female, Negative 2019 35
HTS_TST 35-39, Female, Negative 2019 168
HTS_TST 35-39, Female, Negative 2019 436
HTS_TST 35-39, Female, Negative 2019 9,808
HTS_TST 35-39, Female, Negative 2019 3,635
HTS_TST 35-39, Female, Negative 2019 135
HTS_TST 35-39, Male, Negative 2019 95
HTS_TST 35-39, Male, Negative 2019 5
HTS_TST 35-39, Male, Negative 2019 111
HTS_TST 35-39, Male, Negative 2019 243
HTS_TST 35-39, Male, Negative 2019 6,340
HTS_TST 35-39, Male, Negative 2019 87
HTS_TST 40-49, Female, Negative 2019 45
HTS_TST 40-49, Female, Negative 2019 40
HTS_TST 40-49, Female, Negative 2019 171
HTS_TST 40-49, Female, Negative 2019 391
HTS_TST 40-49, Female, Negative 2019 9,919
HTS_TST 40-49, Female, Negative 2019 3,642
HTS_TST 40-49, Female, Negative 2019 128
HTS_TST 40-49, Male, Negative 2019 90
HTS_TST 40-49, Male, Negative 2019 2
HTS_TST 40-49, Male, Negative 2019 37
HTS_TST 40-49, Male, Negative 2019 81
HTS_TST 40-49, Male, Negative 2019 2,140
HTS_TST 40-49, Male, Negative 2019 30
HTS_TST 50+, Female, Negative 2019 60
HTS_TST 50+, Male, Negative 2019 13
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 349,225
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 32
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 2,345
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 7,245
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 6
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 89
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 905
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 218
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 344
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 408
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 245
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 1,389
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 1,285
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 83
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 18
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 15
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 235
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 50
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 92
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 977
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 524
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 3,324
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 1,692
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 168
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 38
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 6,149
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 1,773
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 2,259
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 14,944
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 21,834
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 80,647
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 42,958
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 4,879
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 1,065
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 3,471
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 29
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 36
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 32
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 56
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 65
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 54
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 60
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 42
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 71
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 81
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 13
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 252
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 37
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 18
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 1
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 886
HTS_TST_POS 15-19, Female, Positive 2019 1
HTS_TST_POS 15-19, Male, Positive 2019 1
HTS_TST_POS 20-24, Female, Positive 2019 5
HTS_TST_POS 20-24, Male, Positive 2019 3
HTS_TST_POS 25-29, Female, Positive 2019 16
HTS_TST_POS 25-29, Female, Positive 2019 6
HTS_TST_POS 25-29, Female, Positive 2019 101
HTS_TST_POS 25-29, Female, Positive 2019 23
HTS_TST_POS 25-29, Female, Positive 2019 364
HTS_TST_POS 25-29, Female, Positive 2019 231
HTS_TST_POS 25-29, Female, Positive 2019 2
HTS_TST_POS 25-29, Male, Positive 2019 19
HTS_TST_POS 25-29, Male, Positive 2019 13
HTS_TST_POS 25-29, Male, Positive 2019 3
HTS_TST_POS 25-29, Male, Positive 2019 259
HTS_TST_POS 30-34, Female, Positive 2019 14
HTS_TST_POS 30-34, Female, Positive 2019 5
HTS_TST_POS 30-34, Female, Positive 2019 118
HTS_TST_POS 30-34, Female, Positive 2019 26
HTS_TST_POS 30-34, Female, Positive 2019 417
HTS_TST_POS 30-34, Female, Positive 2019 2
HTS_TST_POS 30-34, Male, Positive 2019 23
HTS_TST_POS 30-34, Male, Positive 2019 14
HTS_TST_POS 30-34, Male, Positive 2019 3
HTS_TST_POS 30-34, Male, Positive 2019 331
HTS_TST_POS 35-39, Female, Positive 2019 16
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Female, Positive 2019 26
HTS_TST_POS 35-39, Female, Positive 2019 6
HTS_TST_POS 35-39, Female, Positive 2019 150
HTS_TST_POS 35-39, Female, Positive 2019 1
HTS_TST_POS 35-39, Male, Positive 2019 32
HTS_TST_POS 35-39, Male, Positive 2019 14
HTS_TST_POS 35-39, Male, Positive 2019 3
HTS_TST_POS 35-39, Male, Positive 2019 100
HTS_TST_POS 40-49, Female, Positive 2019 15
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Female, Positive 2019 27
HTS_TST_POS 40-49, Female, Positive 2019 8
HTS_TST_POS 40-49, Female, Positive 2019 157
HTS_TST_POS 40-49, Female, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 30
HTS_TST_POS 40-49, Male, Positive 2019 4
HTS_TST_POS 40-49, Male, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 33
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 70
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 65
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 33
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 217
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 113
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 54
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 26
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 24
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 232
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 348
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 1,265
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 692
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 79
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 23
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 25
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 2
PMTCT_ART Already on ART at beginning of current pregnancy 2019 512
PMTCT_ART New on ART 2019 310
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 822
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 24,759
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 71
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 71
PMTCT_EID Sum of Infant Age disaggregates 2019 71
PMTCT_STAT 25-29, Female 2019 3,783
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 114
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 3,622
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 45
PMTCT_STAT 30-34, Female 2019 3,783
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 114
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 3,615
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 45
PMTCT_STAT 35-39, Female 2019 3,783
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 114
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 3,615
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 45
PMTCT_STAT 40-49, Female 2019 3,783
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 114
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 3,620
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 45
PMTCT_STAT By Age (Numerator): 10-14 2019 30
PMTCT_STAT By Age (Numerator): 15-19 2019 2,237
PMTCT_STAT By Age (Numerator): 20-24 2019 7,371
PMTCT_STAT By Age (Numerator): 50+ 2019 8
PMTCT_STAT By Number of known positives: 15-19 2019 10
PMTCT_STAT By Number of known positives: 20-24 2019 79
PMTCT_STAT By Number of new negative: 10-14 2019 28
PMTCT_STAT By Number of new negative: 15-19 2019 2,153
PMTCT_STAT By Number of new negative: 20-24 2019 7,215
PMTCT_STAT By Number of new negative: 50+ 2019 9
PMTCT_STAT By Number of new positives: 15-19 2019 29
PMTCT_STAT By Number of new positives: 20-24 2019 101
PMTCT_STAT Number of new ANC and L&D clients 2019 25,250
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 24,759
PMTCT_STAT_den 25-29, Female 2019 3,853
PMTCT_STAT_den 30-34, Female 2019 3,853
PMTCT_STAT_den 35-39, Female 2019 3,853
PMTCT_STAT_den 40-49, Female 2019 2
PMTCT_STAT_den By Age (Denominator): <10 2019 30
PMTCT_STAT_den By Age (Denominator): <15-19 2019 7,456
PMTCT_STAT_den By Age (Denominator): 10-14 2019 2,335
PMTCT_STAT_den By Age (Denominator): 20-24 2019 3,853
PMTCT_STAT_den By Age (Denominator): 50+ 2019 15
PrEP_NEW 25-29, Female 2019 54
PrEP_NEW 25-29, Male 2019 23
PrEP_NEW 30-34, Female 2019 40
PrEP_NEW 30-34, Male 2019 32
PrEP_NEW 35-39, Female 2019 40
PrEP_NEW 35-39, Male 2019 32
PrEP_NEW 40-49, Female 2019 40
PrEP_NEW 40-49, Male 2019 23
PrEP_NEW Female 15-19 2019 94
PrEP_NEW Female 20-24 2019 322
PrEP_NEW Female 50+ 2019 15
PrEP_NEW FSW 2019 109
PrEP_NEW Male 15-19 2019 8
PrEP_NEW Male 20-24 2019 46
PrEP_NEW Male 50+ 2019 15
PrEP_NEW MSM 2019 54
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 784
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 227
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 321
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 548
TB_PREV By Age/Sex (Numerator): <15, Female 2019 324
TB_PREV By Age/Sex (Numerator): <15, Male 2019 299
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 4,488
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 1,889
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 7,000
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 7,000
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 324
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 299
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 4,488
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 1,889
TB_PREV_den IPT, Life-long ART, New, Positive 2019 7,000
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 81
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 534
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 85
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,186
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 1,886
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 1,951
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 99
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 545
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 88
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,219
TX_CURR 25-29, Female, Positive 2019 5,381
TX_CURR 25-29, Male, Positive 2019 963
TX_CURR 30-34, Female, Positive 2019 4,062
TX_CURR 30-34, Male, Positive 2019 1,494
TX_CURR 35-39, Female, Positive 2019 4,062
TX_CURR 35-39, Male, Positive 2019 1,494
TX_CURR 40-49, Female, Positive 2019 2,766
TX_CURR 40-49, Male, Positive 2019 1,494
TX_CURR Age/Sex: <1 2019 10
TX_CURR Age/Sex: <1-9 2019 724
TX_CURR Age/Sex: 10-14 Female 2019 499
TX_CURR Age/Sex: 10-14 Male 2019 501
TX_CURR Age/Sex: 15-19 Female 2019 405
TX_CURR Age/Sex: 15-19 Male 2019 285
TX_CURR Age/Sex: 20-24 Female 2019 1,135
TX_CURR Age/Sex: 20-24 Male 2019 374
TX_CURR Age/Sex: 50+ Female 2019 2,213
TX_CURR Age/Sex: 50+ Male 2019 545
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 28,407
TX_CURR Sum of age/sex disaggregates 2019 690
TX_NEW 25-29, Female, Positive 2019 776
TX_NEW 25-29, Male, Positive 2019 112
TX_NEW 30-34, Female, Positive 2019 886
TX_NEW 30-34, Male, Positive 2019 135
TX_NEW 35-39, Female, Positive 2019 222
TX_NEW 35-39, Male, Positive 2019 135
TX_NEW 40-49, Female, Positive 2019 222
TX_NEW 40-49, Male, Positive 2019 45
TX_NEW Breastfeeding status 2019 67
TX_NEW By Age/Sex: <1 2019 17
TX_NEW By Age/Sex: 1-9 2019 43
TX_NEW By Age/Sex: 10-14 Female 2019 9
TX_NEW By Age/Sex: 10-14 Male 2019 14
TX_NEW By Age/Sex: 15-19 Female 2019 507
TX_NEW By Age/Sex: 15-19 Male 2019 292
TX_NEW By Age/Sex: 20-24 Female 2019 1,750
TX_NEW By Age/Sex: 20-24 Male 2019 936
TX_NEW By Age/Sex: 50+ Female 2019 110
TX_NEW By Age/Sex: 50+ Male 2019 22
TX_NEW FSW 2019 5
TX_NEW MSM 2019 3
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 6,233
TX_NEW People in prisons and other enclosed settings 2019 101
TX_NEW Pregnancy status 2019 305
TX_NEW Sum of Age/Sex disaggregates 2019 3,640
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 28,820
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 97
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 935
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 95
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 858
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 1,785
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 16,021
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 903
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 8,126
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 132
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 55
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 3,186
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,649
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 5,022
TX_RET Numerator by Status: Breastfeeding 2019 18
TX_RET Numerator by Status: Pregnant 2019 287
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 5,602
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 134
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 69
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 3,557
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,842
TX_RET_den Denominator by Status: Breastfeeding 2019 25
TX_RET_den Denominator by Status: Pregnant 2019 399
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 28,409
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 949
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 922
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 17,585
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 8,697
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 1,032
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 107
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 1,143
Cross Cutting Budget Categories and Known Amounts Total: $853,093
Gender: Gender Based Violence (GBV) $128,000
GBV Prevention
Implementation
Capacity building
Post GBV Care
Implementation
Capacity building
Human Resources for Health $725,093